Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Corporate Presentation

Updated as of June 11, 2018

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.


At Oasmia, we’re developing the next generation of drugs with focus on oncology.


At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share


Update regarding the Market Authorization Application of Apealea in the European Union

With reference to yesterday’s communicated agenda for this week’s meeting by the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency (EMA) has informed Oasmia Phar...
Read more

Oasmia completes a private placement of new convertible instruments in the amount SEK 35.2 million

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the total amount of SEK 35,200,000 with...
Read more

Oasmia Pharmaceutical AB (publ)

Interim report for the period May – July 2018
Read more
To news archive